197 related articles for article (PubMed ID: 38138199)
21. Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients.
FitzGerald JD; Grossman JM
Lupus; 1999; 8(8):638-44. PubMed ID: 10568901
[TBL] [Abstract][Full Text] [Related]
22. Information on diagnosis and management of systemic lupus erythematosus derived from the routine measurement of 8 nuclear autoantibodies.
Ignat GP; Rat AC; Sychra JJ; Vo J; Varga J; Teodorescu M
J Rheumatol; 2003 Aug; 30(8):1761-9. PubMed ID: 12913932
[TBL] [Abstract][Full Text] [Related]
23. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial.
Jolly M; Annapureddy N; Arnaud L; Devilliers H
Lupus; 2019 Dec; 28(14):1628-1639. PubMed ID: 31674267
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary involvement: A potential independent factor for quality of life in systemic lupus erythematosus.
Osman HM; Abdel-Nasser AM; Kasem AH; Elameen NF; Omar GM
Lupus; 2023 Feb; 32(2):198-206. PubMed ID: 36460049
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the incidence of discoid lupus erythematosus in patients with systemic lupus erythematosus and its relationship to disease activity.
Saghafi M; Hashemzadeh K; Sedighi S; Yazdanpanah MJ; Rezaieyazdi Z; Sahebari M; Esmaily H
J Cutan Med Surg; 2014 Oct; 18(5):316-9. PubMed ID: 25186992
[TBL] [Abstract][Full Text] [Related]
26. Translation, cultural adaptation and validation of the Systemic Lupus Erythematosus Activity Questionnaire (SLAQ) in a cohort of Italian systemic lupus erythematosus patients.
Tani C; Vagelli R; Stagnaro C; Carli L; Lorenzoni V; Drago F; Doherty W; McSorley MR; Marconcini L; Della Rossa A; Turchetti G; Mosca M
Lupus; 2018 Sep; 27(10):1735-1741. PubMed ID: 30045666
[TBL] [Abstract][Full Text] [Related]
27. Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients.
Ceccarelli F; Picciariello L; Natalucci F; Moretti V; Spinelli FR; Alessandri C; Conti F
Clin Exp Rheumatol; 2024 May; ():. PubMed ID: 38819948
[TBL] [Abstract][Full Text] [Related]
28. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study.
Inês L; Duarte C; Silva RS; Teixeira AS; Fonseca FP; da Silva JA
Rheumatology (Oxford); 2014 Jan; 53(1):85-9. PubMed ID: 24067885
[TBL] [Abstract][Full Text] [Related]
29. Cross-cultural validation of a disease-specific patient-reported outcome measure for systemic lupus erythematosus in Canada.
Bourré-Tessier J; Clarke AE; Mikolaitis-Preuss RA; Kosinski M; Bernatsky S; Block JA; Jolly M
J Rheumatol; 2013 Aug; 40(8):1327-33. PubMed ID: 23772082
[TBL] [Abstract][Full Text] [Related]
30. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study.
Zen M; Bassi N; Nalotto L; Canova M; Bettio S; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
Clin Exp Rheumatol; 2012; 30(6):856-63. PubMed ID: 22765883
[TBL] [Abstract][Full Text] [Related]
31. The Fatigue Assessment Scale as a simple and reliable tool in systemic lupus erythematosus: a cross-sectional study.
Horisberger A; Courvoisier D; Ribi C
Arthritis Res Ther; 2019 Mar; 21(1):80. PubMed ID: 30909957
[TBL] [Abstract][Full Text] [Related]
32. QRISK3-based analysis of cardiovascular risk factors in patients with long-term but well-controlled systemic lupus erythematosus.
Wang SL; Li W; Li TF; Liang X; Yan YL; Liu SY
Am J Transl Res; 2022; 14(5):3247-3260. PubMed ID: 35702101
[TBL] [Abstract][Full Text] [Related]
33. Predicting lupus flares: epidemiological and disease related risk factors.
Andrade SO; Julio PR; Nunes de Paula Ferreira D; Appenzeller S
Expert Rev Clin Immunol; 2021 Feb; 17(2):143-153. PubMed ID: 33393397
[No Abstract] [Full Text] [Related]
34. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
Castrejón I; Tani C; Jolly M; Huang A; Mosca M
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-85-95. PubMed ID: 25365095
[TBL] [Abstract][Full Text] [Related]
35. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
36. Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus.
Giangreco D; Devilliers H; Annapureddy N; Block JA; Jolly M
Lupus; 2015 Dec; 24(14):1486-91. PubMed ID: 26162686
[TBL] [Abstract][Full Text] [Related]
37. Septicaemia is associated with increased disease activity and mortality in systemic lupus erythematosus: a retrospective analysis from Taiwan.
Tsai PH; Jang SS; Liou LB
Lupus; 2020 Feb; 29(2):191-198. PubMed ID: 31959041
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous, systemic features and laboratory characteristics of late- versus adult-onset systemic lupus erythematosus in 1006 Thai patients.
Chanprapaph K; Tubtieng I; Pratumchat N; Thadanipon K; Rattanakaemakorn P; Suchonwanit P
Lupus; 2021 Apr; 30(5):785-794. PubMed ID: 33554715
[TBL] [Abstract][Full Text] [Related]
39. Serum pentraxin 3 in systemic lupus erythematosus: A potential indicator of cutaneous disease activity.
Ismail SA; Awad SM; Gamal RM; Gaber MA; Hussein SM; Hammam N
Lupus; 2023 Jun; 32(7):873-879. PubMed ID: 37183233
[TBL] [Abstract][Full Text] [Related]
40. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus.
Yoshida T; Tsuji H; Onishi A; Takase Y; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Tanaka M; Yoshifuji H; Morinobu A
Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35961691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
